Congress Enters Contentious Debate on Biosimilar Naming: Bill Provision Sides With Brand-Name Companies Over USP

Documenti analoghi

• Generics Companies Press for REMS Relief: Potential Law Would Clarify When Brand-Name Manufacturers Must Supply Drug Samples
  di: Barlas, Stephen
  Pubblicazione: (2016)
• Conflicting Opinions Flood FDA on Its Proposal for Biosimilar Naming
  di: Barlas, Stephen
  Pubblicazione: (2016)
• FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars
  di: Barlas, Stephen
  Pubblicazione: (2017)
• FTC Versus Congress: The Biosimilars Debate
  di: CARR, KATHLEEN, et al.
  Pubblicazione: (2009)
• Brand-Name Generic Deals Face End of the Line: Congress Likely to Ban Exclusion Payments
  di: Barlas, Stephen
  Pubblicazione: (2009)